BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Low dose of BI 1356 BSDrug: Medium dose of BI 1356 BSDrug: High dose of BI 1356 BSDrug: Placebo
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT02183324
Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Phase 2
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7
- Registration Number
- NCT02182869
Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male Volunteers
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT02182076
Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT02182401
Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT02182323
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment
Phase 1
Completed
- Conditions
- Renal Insufficiency
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 35
- Registration Number
- NCT02182024
Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 101
- Registration Number
- NCT02182518
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
Phase 3
Completed
- Conditions
- Myocardial Infarction
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5989
- Registration Number
- NCT02181985
Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Ba253BINEB
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT02182635
Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Ba253BINEBDrug: Ba253MDI
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 163
- Registration Number
- NCT02182583
© Copyright 2025. All Rights Reserved by MedPath